Acute kidney injury (AKI) after cardiac surgery is a serious complication that is closely associated with postoperative death. In previous studies that evaluated risk factors for AKI, most of the identified risk factors were not modifiable (eg, diabetes mellitus, preexisting kidney disease). In the present multicenter study of 3500 adult patients undergoing cardiac surgery in 2004, we focused on identifying potentially modifiable risk factors for postoperative AKI. We found that AKI, as defined by consensus-based criteria (Ͼ25%, Ͼ50%, and Ͼ75% decrease in estimated glomerular filtration rate or need for dialysis within 1 week of surgery), was independently associated with a Ͼ4-fold increase in death rates. Three common and potentially modifiable variables (preoperative anemia, red blood cell transfusions, and surgical reexploration) were highly associated with AKI, even after adjustment for other perioperative risk factors (eg, preoperative intra-aortic balloon pump, cardiopulmonary bypass duration). Given these results, we propose that randomized trials are now needed to determine whether interventions that modify these risk factors might also prevent AKI after cardiac surgery. See p 495.
Declining Severity of Myocardial Infarction From 1987 to 2002: The Atherosclerosis Risk in Communities (ARIC) Study
Death rates for coronary heart disease have been declining in the United States. From a public health standpoint, it is important to identify factors that are contributing to this decline. We investigated whether a reduction in severity of myocardial infarction may contribute to lower death rates. We tracked residents 35 to 74 years of age in the community surveillance component of the Atherosclerosis Risk in Communities (ARIC) Study who were hospitalized with acute incident myocardial infarction and looked at severity indicators abstracted from hospital charts. Included in these were ECG, biomarker, and hemodynamic indicators. With few exceptions, the myocardial infarction severity indicators suggested a significant decline in the severity of myocardial infarction during the period of 1987 to 2002. This reduction in severity may have contributed, along with other factors, to the decline in death rates. There may be several reasons for a decline in severity of incident myocardial infarction; the findings from the present study suggest that 1 factor may be better primary prevention and support ongoing research to determine how preventive care may further reduce coronary heart disease death. See p 503.
Long-Term Trends In First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People
The rate of hospitalization for heart failure (HF) rose until the mid 1990s, and it was feared we were in the midst of a HF epidemic. Recently, reports have suggested that rates were beginning to fall. In the present study, all patients in Scotland (population 5.1 million) hospitalized with a first episode of HF between 1986 to 2003 were followed up until death or the end of 2004. Prescriptions of evidence-based treatments issued from 1997 to 2003 by a sample of primary care practices were also examined. A total of 116 556 individuals (52.6% women) had a first hospital discharge for HF. From 1986 to 2003, age-adjusted first hospitalization rates for HF (per 100 000) in men rose from 124 (95% CI 119 to 129) in 1986 to 162 (95% CI 157 to 168) in 1994 and then fell to 105 (95% CI 101 to 109) in 2003. In women, they rose from 128 (95% CI 123 to 132) in 1986 to 160 (95% CI 155 to 165) in 1993, falling to 101 (95% CI 97 to 105) in 2003. Adjusted 30-day, 1-year, and 5-year case fatality fell in both men and women over the period. Median survival and age at death also increased. Age-adjusted prescribing rates for angiotensin-converting enzyme inhibitors, ␤-blockers, and spironolactone increased from 1997 to 2003 (all PϽ0.0001 for trend). These findings suggest but cannot prove that improvements in the prevention and treatment of HF may have had progressive, sustained effects on outcomes at the population level. However, average survival remains poor after hospitalization for a first episode of HF (median survival 2.34 years in men and 1.79 years in women), which indicates that further improvements are still possible and new treatments are still required if the prognosis of this deadly condition is to continue to improve. See p 515.
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment
Enzyme replacement therapy with recombinant ␣-galactosidase A clears microvascular deposits of globotriaosylceramide in biopsies of kidney, skin, and heart of most Fabry patients. Clinically, it could be demonstrated that enzyme replacement therapy reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry cardiomyopathy during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown. The present study shows that a baseline assessment of cardiac morphology and function before the start of enzyme replacement therapy is necessary. Thus, knowledge of the presence or absence of myocardial fibrosis (which is typical for a late stage of this disease) is crucial with respect to treatment expectations. Myocardial fibrosis can be visualized directly with the magnetic resonance imaging late-enhancement technique. In addition, the functional consequences of fibrosis can be quantified by ultrasonic strainrate imaging. Only Fabry patients with no fibrosis before enzyme replacement therapy show a sustained improvement in regional myocardial function and exercise capacity in the long term. Thus, in Fabry disease, early is probably superior to late treatment to improve cardiac morphology, function, and exercise capacity. See p 524.
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
Left ventricular hypertrophy is a marker of cardiac end-organ damage that is associated with an increased risk of morbidity and mortality. Aliskiren is a novel, orally active, direct renin inhibitor that blocks the renin-angiotensin-aldosterone system proximally. To determine whether aliskiren alone or in combination with the angiotensin receptor blocker losartan would be better than losartan alone in regressing left ventricular hypertrophy in hypertensive patients, we randomized 465 to receive aliskiren 300 mg daily, losartan 100 mg daily, or their combination for 9 months and assessed left ventricular mass at baseline and at follow-up using cardiac magnetic resonance imaging. We found a significant reduction in blood pressure and left ventricular mass in all groups. We found no incremental benefit for combination therapy over losartan 487
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Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity
Together, obesity and type 2 diabetes create a state of chronic low-grade inflammation that has both genetic and environmental determinants. Although the role of diet and exercise as environmental determinants is defined, the interaction between particulate air pollution (PM 2.5 ) and other metabolic determinants of obesity/insulin resistance has not yet been elucidated. In this experiment, we exposed C57BL/6 mice fed high-fat chow to concentrated ambient PM 2.5 or filtered air for 24 weeks and demonstrated that PM 2.5 -exposed mice exhibited marked whole-body insulin resistance, increased visceral adiposity and visceral adipose inflammation concomitant with vascular relaxation abnormalities, and enhanced monocyte adhesion to microcirculatory beds. Our findings provide new insights into a potential role for PM 2.5 exposure in the pathogenesis of diabetes/insulin resistance and further our understanding of how inhaled particulates may modulate responses in distant target organs. See p 538.
Endothelial Progenitor Cells Restore Renal Function in Chronic Experimental Renovascular Disease
Significant attention has been directed to the biologic and therapeutic capabilities of progenitor cells. Endothelial progenitor cells mobilized endogenously in response to ischemia play a crucial role in augmenting neovascularization of ischemic tissues and repair of the vessel wall after endothelial cell denudation. A large body of experimental and clinical evidence accumulated over the last 10 years demonstrating that administration of endothelial progenitor cells could improve the function of the ischemic tissues. The present study tested the feasibility of using progenitor cells to treat the obstructed kidney in a model of chronic renovascular disease. This disease is difficult to treat and may induce hypertension and renal injury, leading to end-stage renal disease. In this model, a single intrarenal administration of endothelial progenitor cells restored renal hemodynamics and function, preserved renal microvascular architecture, and attenuated fibrosis of the ischemic kidney. The demonstrated capability of endothelial progenitor cells to restore vascular integrity and preserve the stenotic kidney may constitute an important step for designing novel therapeutic measures for management of patients with renovascular disease. See p 547.
Discordant Secular Trends in Elevated Blood Pressure and Obesity in Children and Adolescents in a Rapidly Developing Country
The effect of the increasing prevalence of obesity on blood pressure (BP) levels in the population is complex. In children, some studies in the United States suggest that BP increased recently, likely because of the obesity epidemic, but other studies in the United States and elsewhere show no increase in BP levels in the last decades despite increasing average body mass index. In a population-based study of 25 586 children 4 to 18 years of age in the Seychelles (a rapidly developing country in the Indian Ocean, African region), the prevalence of obesity increased largely between 1998 and 2006, yet systolic and diastolic BPs did not increase. During this period, systolic BP shifted toward lower values across the entire distribution of body mass index. Our study was not designed to investigate factors underlying these divergent trends in BP and obesity. However, the identification of potential preventable determinants that may mitigate the effect of increasing body mass index on BP trends might help develop new strategies for the primary prevention of hypertension and related diseases. Our findings also contribute to the current debate on the scope and scale of the association between the obesity epidemic and cardiometabolic outcomes in populations. See p 558.
Altered Bone Morphogenetic Protein and Transforming Growth Factor-␤ Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease
Recent genetic studies confirmed that mutations in receptors for the transforming growth factor (TGF)-␤ family, particularly the bone morphogenetic protein (BMP) type II receptor, are major causes of pulmonary arterial hypertension. The present study characterizes the changes in TGF-␤ and BMP signaling in 2 widely used rat models of pulmonary hypertension, the chronically hypoxic rat and pulmonary hypertension induced by monocrotaline. In both models, we found evidence for a reduction in BMP signaling and an increase in TGF-␤ signaling, but the changes were much more marked in the monocrotaline model. The monocrotaline model is characterized by inflammation, particularly recruitment of macrophages to the lung, which we show to be 1 of the main sources of increased TGF-␤. We then determined the efficacy of IN-1233, a small-molecule inhibitor of the TGF-␤ type I receptor activin receptor-like kinase-5, to prevent and reverse pulmonary hypertension in vivo in the chronic hypoxic and monocrotaline models. IN-1233 prevented the development of pulmonary hypertension when administered early and prevented progression of pulmonary hypertension when administered later in the course of monocrotaline-induced disease. No effect was seen in the hypoxic model. In the monocrotaline model, we confirmed that IN-1233 inhibited activation of TGF-␤ signaling via Smad proteins and inhibited the transcription of TGF-␤-driven genes. These studies confirm that disruption of BMP/TGF-␤ signaling accompanies the development of pulmonary hypertension in these animal models and that inhibition of TGF-␤ signaling may be of therapeutic benefit in some patients with pulmonary arterial hypertension. See p 566.
Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury
Smooth muscle cell proliferation contributes to the initiation of atherosclerosis and the failure of interventional approaches used to treat occlusive atherosclerotic diseases, including in-stent restenosis after percutaneous coronary intervention, vein-graft atherosclerosis, and transplant vasculopathy. Therefore, understanding the molecular mechanisms governing smooth muscle cell proliferation is of particular interest for the development of novel therapeutic approaches to prevent atherosclerosis and its complications. In previous studies, NR4A receptors have been characterized as key regulators of macrophage inflammation and smooth muscle cell proliferation. From this evidence, we hypothesized that neuron-derived orphan receptor-1 (NOR1) deficiency might prevent pathological vascular remodeling. In the present study, we confirm this concept and demonstrate that NOR1 deficiency prevents neointima formation in response to injury as a result of altered cyclin D1 expression. These experiments provide the first evidence that modulation of NOR1 expression might provide a rational approach to prevent proliferative vascular disease. See p 577.
